Metsera
AcquiredReducing the burden of obesity
New York, United States · Founded 2022 · $505.0M raised
- Headquarters
- New York, New York
- Employees
- 11–50
- Founded
- 2022
- Business Model
- Other
- Website
- metsera.com
- Total Funding
- $505.0M
- Last Round
- $215.0M Series BNov 2024
- Rounds
- 2
- Acquired by
- PfizerSep 2025 · $4.9B
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Metsera is a clinical-stage biotechnology company focused on developing next-generation oral and injectable nutrient-stimulated hormone (NuSH) therapies for obesity and metabolic diseases. Their portfolio aims to reduce barriers to adoption with improved scalability, potency, and tolerability. Now part of Pfizer following acquisition.
Summary
Metsera is a Biotech company based in New York, United States, founded in 2022. It has raised $505.0M in total across 2 rounds, most recently a $215.0M Series B round in Nov 2024. Investors include Pfizer Ventures, OrbiMed and ARCH Venture Partners.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Sep 2025
Sign up to see all 4 events
Funding: Seed through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/metsera"><img src="https://indexed.vc/api/badge/company/metsera" alt="Metsera on Indexed.vc" width="260" height="76" /></a>